This DILIsym model supported the hypothesis that impaired biliary efflux increased susceptibility to tolvaptan-associated hepatotoxicity observed in patients with ADPKD, and MRP2 played a more prominent role in tolvaptan-associated liver injury owing to the inhibition of DM-4103 on MRP2 [92]. Here, ABCC2 is linked to autosomal dominant polycystic kidney disease.